M Pharmaceutical, Inc. has entered an agreement to acquire the assets of Cincinnati-based R&D partnership 40J’s LLC and its related companies and technologies for approximately 80 million shares and $1.5 million in cash to be issued or paid during the next two years, together with certain milestone payments. M Pharmaceutical will acquire all of the worldwide rights to these products and technologies. The transaction is subject to customary closing conditions.
 
40J’s companies and principals have developed numerous patented and patent pending technologies for a range of medical concerns with a focus on female and male reproductive health, diabetes, and weight loss, among others.
 
“This acquisition is a very exciting advancement for M Pharma,” said Gary Thompson chief executive officer of M Pharmaceutical USA. “Like M Pharma, 40J’s is a company committed to developing and commercializing innovative treatments and technologies to offer patients and consumers effective solutions to quality of life concerns; these are based on the overreaching principles of reduced invasiveness and improved effectiveness. The companies’ extensive list of patented and patent pending technologies not only builds upon M Pharma’s current pipeline of product innovation, but also brings current distribution partners & ongoing business development, harmonizes operations and R&D initiatives, and adds existing inventory & revenue to our bottom line,” said Mr. Thompson.